Introduction {#sec1}
============

*Toxoplasma gondii* as an obligate intracellular protozoan with a worldwide distribution can infect virtually all warm-blooded animals and human. One-third of the human population is assumed to be infected with *T. gondii* \[[@ref1]\]. In immunocompetent individuals, clinical symptoms of toxoplasmosis present as mild and self-limiting, including fever, malaise and lymphadenopathy. However, infection is usually more severe in immunocompromised people and pregnant women. In these groups, the infection is accompanied by more complications, such as encephalitis, retinochoroiditis, foetus abortion, splenomegaly and pneumonitis \[[@ref2]\].

The number and genetic diversity of parasites play an important role in pathogenesis of *T. gondii* \[[@ref3]\]. Identifying the genotypes of *T. gondii* using molecular technologies is invaluable in epidemiological studies. These techniques include multilocus polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), microsatellite analysis, random amplified polymorphic (RAPD), multilocus sequence typing (MLST) and high-resolution melting (HRM) analysis \[[@ref4]\].

The first genotyping studies on *T. gondii* strains in France and the United States of America demonstrated a clonal population structure with three main lineages namely type I, II and III \[[@ref5]\]. Despite the sexual phase and global distribution of *T. gondii*, the population structure of this parasite is explained as highly clonal with low genetic diversity \[[@ref6]\]. This was found in genetic researches on isolates from Europe and USA which classified the isolates as three major genotypes of type I, II and III (approximately 90%) \[[@ref7]\].

More genetic variation of *T. gondii*, except for the three main lineages, was found in the other continents. These 'new' genotypes were designated as atypical, exotic, recombinant or non-archetypal genotypes \[[@ref8], [@ref9]\]. Multilocus PCR-RFLP analysis of 10 gene markers in 1457 *T. gondii* isolates worldwide revealed 189 different genotypes. The data of these genotypes are displayed in ToxoDB \[[@ref10]\].

Numerous studies were performed on *T. gondii* genotyping in different groups of patients and healthy individuals. However, there is no exhaustive documented data regarding this subject. Therefore, this study aims to provide a summary of the available data on genotypes of *T. gondii* in human. This study was carried out to evaluate the predominant genotypes in different continents of the world. Moreover, the prevalence of genotypes is assessed in various groups of human toxoplasmosis, namely immunocompromised, congenital, ocular toxoplasmosis, cancer and immunocompetent.

Methods {#sec2}
=======

This review followed the preferred reporting items for systematic reviews (PRISMA) guidelines \[[@ref11]\].

Literature search, study selection and data extraction {#sec2-1}
------------------------------------------------------

We searched MEDLINE in PubMed, Scopus, Science Direct, Web of Science and Google Scholar during 1995--August 2017. The utilised keywords entailed *Toxoplasma gondii*, toxoplasmosis, genotype, genotyping, molecular characterisation, human, individuals, patients, pregnancy, women, congenital, cancer, AIDS, HIV, immunocompromised and ocular toxoplasmosis. We searched the mentioned keywords alone and in combination with the others.

In this systematic review, the exclusion criteria encompassed not describing the *T. gondii* genotypes in human, in addition to using genetic characterisation methods with less than five gene markers. To collect precise information, a comprehensive search was completed on all published and unpublished articles including full texts, abstracts and parasitology congresses summaries. All the data were collected from English language articles. We defined a protocol for data extraction and two authors assessed the obtained data independently. Afterwards the disagreements between the comments were discussed and resolved.

The data extracted from studies encompassed year, first author, country and continent, total sample size, methods, genotypes of *T. gondii*, type of patients and molecular markers used for genotyping in the study.

The genotypes were classified as classical types I, II, III, mix/recombinant (i.e. I&III, I&II, II&III/exotic and unknown) atypical, Africa I and ToxoDB genotype. A protocol of this systematic review with CRD 42017070501 code is available in international prospective register of systematic reviews (PROSPERO, <http://www.crd.york.ac.uk/prospero>) \[[@ref12]\].

Results {#sec3}
=======

A graphic summary of this study on genetic diversity of *T. gondii* is shown in [Figure 1](#fig01){ref-type="fig"}. Overall, we selected 4731 studies for this systematic review. After screening, 26 papers were eligible as genotyping studies on *T. gondii* in human samples ([Table 1](#tab01){ref-type="table"} and [Fig. 2](#fig02){ref-type="fig"}). From these papers, we collected 371 individual genotyping data, 286 of which being about clonal genotyping (I, II, III, mix/recombinant, Africa I and atypical) and 85 about ToxoDB genotyping (genotypes \#1--\#231). Fig. 1.Graphic summary of the study on genetic diversity of *T. gondii* in human. Fig. 2.PRISMA flow diagram describing the study design. Table 1.Overview of the included studies regarding genotyping *T. gondii* isolates from human and summary of the main findingsNo.AuthorPatients groupMethods for genotypingMolecular markers for genotypingNo. of isolatesNo. (%) genotype1Howe and Sibley \[[@ref13]\]AIDS/congenital toxoplasmosisPCR-RFLPSAG1, SAG2, L328, ROP1, 850, 626816 (23.5) I, 43 (63.2) II, 9 (13.3) III2Grigg *et al*. \[[@ref9]\]Ocular toxoplasmosisPCR-RFLPB1, SAG1, SAG2, SAG3, SAG4123 (25) I, 3 (25) II, 1 (8.4) III, 5 (41.6) I&III3Ajzenberg *et al*. \[[@ref14]\]Congenital toxoplasmosisPCR of MS markersTUB2, W35, TG-MA, w35487, N60608, N82375, N83021, N61191, AA5191508673 (84.8) II, 7 (8.1) I, 2 (2.3) III, 4 (4.6) atypical4De melo Ferreira \[[@ref15]\]Congenital toxoplasmosisPCR-RFLPSAG1, SAG2, SAG3, B1, cB21-4, cS10-A6, GRA6, L36344 (100) atypical5Khan *et al*. \[[@ref16]\]Ocular toxoplasmosisPCR-RFLP5′SAG2, 3′SAG2, BTUB, GRA6, SAG3113 (27.3) I, 2 (18.1) II, 3 (27.3) III, 3 (27.3) I&III6Nowakowske *et al*. \[[@ref17]\]NewbornsPCR-RFLP3′SAG2, 5′SAG2, SAG3, BTUB, GRA699 (100) III7Djurković-Djaković *et al*. \[[@ref18]\]Congenital toxoplasmosisPCR-RFLP5′SAG2, 3′SAG2, BTUB, SAG3, GRA611 (100) II8Genot *et al*. \[[@ref19]\]AIDSPCR of MS markersTUB2, TgM-A, W35, B17, B1811 (100) I&III9Demar *et al*. \[[@ref20]\]Congenital immunocompetentPCR of MS markersTUB2, W35, TgM-A, B18, B171111 (100) atypical10Zhou *et al*. \[[@ref21]\]NDMn-PCR-RFLPSAG1, SAG2, SAG3, BTUB, GRA6, c22-8, c29-2, L358, PK1, Apico31 (33.3) \#1, 1 (33.3) \#3, 1 (33.3) \#411Boughattes *et al*. \[[@ref22]\]Congenital toxoplasmosisPCR-RFLP3′SAG2, 5′SAG2, SAG3, BTUB, GRA6, APICO141 (7.14) I, 7 (50) I&III, 3 (21.4) I&II, 3 (21.4) I&II + I&III12Ferreira *et al*. \[[@ref23]\]AIDS, congenital, pregnant, ocular, acute toxoplasmosisMn-PCR-RFLPSAG1, SAG2, SAG3, BTUB, GRA6, C22-2, C29-2, L358, PK1, APICO2018 (90) \#65, 1 (5) \#71, 1 (5) \#613Boughattes *et al*. \[[@ref24]\]Congenital toxoplasmosisPCR-RFLP3′SAG2, 5′SAG2, SAG3, AK69, APICO, UPRT111 (100) I&III14Boughattes *et al*. \[[@ref25]\]Pregnant and diabeticPCR-RFLP3′SAG2, 5′SAG2, SAG2, SAG3, GRA6, BTUB, APICO, PK1, KT850, UPRT111 (100) atypical15Fekkar *et al*. \[[@ref26]\]Ocular toxoplasmosisPCR of MS markersTUB2, W35, TG-MA, B18, B171310 (76.9) II, 1 (7.7) II&III, 2 (15.4) Africa I16Carneiro *et al*. \[[@ref27]\]NewbornsMn-PCR-RFLP3′SAG2, 5′SAG2, SAG1, SAG3, SAG2, GRA6, L356, APICO, C29-2, C22-9, PK1257 (28) \#11, 1 (4) \#8, 3 (12) \#206, 2 (8) \#41, 2 (8) \#108, 1 (4) \#67, 1 (4) \#207, 1 (4) \#162, 1 (4) \#208, 1 (4) \#36, 1 (4) \#209, 1 (4) \#210, 1 (4) \#211, 1 (4) \#212, 1 (4) (mix/recombinant)18Wang *et al*. \[[@ref28]\]AIDS/cancerMn-PCR-RFLPSAG1, SAG2, SAG3, BTUB, GRA6, C22-2, C29-2, L358, PK1, APICO41 (25) \#1, 1 (25) \#9, 1 (25) \#10, 1 (25) \#20419Costache *et al*. \[[@ref29]\]Congenital toxoplasmosisPCR of MS markersTUB2, W35, TG-MA, w35487, N60608, N82375, N83021, N61191, AA51915011 (100) II20Döşkaya *et al*. \[[@ref30]\]Congenital toxoplasmosisPCR of MS markersTUB-2, W35, TgM-A, B18, B17, M33, IV.1, XI.1, M48, M102, N60, N82, AA, N61, N8322 (100) Africa I21Pardini *et al*. \[[@ref31]\]Congenital toxoplasmosisPCR-RFLPSAG2, SAG3, BTUB, GRA6, c29-2, c22-8, L358, PK1, Apico11 (100) III22Higa *et al*. \[[@ref32]\]Congenital toxoplasmosisMn-PCR-RFLPSAG1, SAG2, SAG3, BTUB, GRA6, C22-2, C29-2, L358, PK1, APICO33 (100) \#16623Silva *et al*. \[[@ref33]\]Congenital toxoplasmosisMn-PCR-RFLPSAG1, 5′SAG2, 3′SAG2, SAG2 alt, SAG3, BTUB, GRA6, c22-8, c29-2, L358, PK1, Apico42 (50) \#108, 1 (25) \# 206, 1 (25) \# 22924Yeraa *et al*. \[[@ref34]\]Congenital toxoplasmosisPCR of MS markersTUB2, W35, TgM-A, B18, B17, M33, IV.1, XI.1, M48, M102, N60, N82, AA, N61, N8322 (100) atypical25Wang *et al*. \[[@ref35]\]CancerMn- PCR-RFLPSAG1, SAG2, SAG3, BTUB, GRA6, C22-2, C29-2, L358, PK1, APICO99 (100) \#926Cong *et al*. \[[@ref36]\]CancerMn-PCR-RFLPSAG1, SAG2, SAG3, BTUB, GRA6, C22-2, C29-2, L358, PK1, APICO178 (47.1) \#10, 8 (47.1) \#9, 1 (5.8) (type I variant)27Virales *et al*. \[[@ref37]\]Congenital toxoplasmosisPCR-RFLP/PCR of MS markersSAG2, TUB, TgM, W35, B17, B18486 (12.5) I, 32 (66.6) II, 6 (12.5) I&II, 4 (8.3) I&III[^1]

Out of 286 cases, in clonal genotyping using PCR-RFLP based on multilocus typing (i.e. more than five gene markers) and microsatellite markers, 166 (58%), 36 (12.6%), 34 (11.9%), 24 (8.4%), 22 (7.7%) and 4 (1.4%) were infected with types II, I, mix/recombinant, III, atypical and Africa I type, respectively ([Table 2](#tab02){ref-type="table"}). The global prevalence rate of *T. gondii* clonal genotypes in different continents is indicated in [Figure 3](#fig03){ref-type="fig"}. The most prevalent types were I and III reported from America (19/97, 19.6% and 12/97, 12.4%, respectively) and type II from Europe (120/173, 69.4%) ([Table 3](#tab03){ref-type="table"}). Fig. 3.Geographical distribution of *T. gondii* strains in the world; sizes of pie charts correlate with the total number of isolates for each country; colours indicate different genotypes. Table 2.Clonal genotyping of *T. gondii* based on multilocus PCR-RFLP and microsatellite in different groupsGroupAuthorCountryNo. of isolatesType I\
No. (%)Type II\
No. (%)Type III\
No. (%)Mix/recombinant, Africa I and atypical\
No. (%)CongenitalHowe and Sibley \[[@ref13]\]USA4110 (24.4)25 (61)6 (14.6)Ajzenberg *et al*. \[[@ref14]\]France867 (8.1)73 (84.9)2 (2.3)4 (4.6) atypicalFerreira *et al*. \[[@ref23]\]Brazil44 (100) atypicalNowakowske *et al*. \[[@ref17]\]Poland99 (100)Djurković-Djaković *et al*. \[[@ref18]\]Serbia11 (100)Demar *et al*. \[[@ref20]\]French Guiana33 (100) atypicalBoughattes *et al*. \[[@ref22]\]Tunisia141 (7.1)13 (50) mix/recombinantBoughattes *et al*. \[[@ref24]\]Tunisia11 (100) mix/recombinantBoughattes *et al*. \[[@ref24]\]Tunisia11 (100) atypicalCostache *et al*. \[[@ref29]\]Romania11 (100)Pardini *et al*. \[[@ref31]\]Argentina11 (100)Döşkaya *et al*. \[[@ref30]\]Turkey22 (100) Africa IYera *et al*. \[[@ref34]\]French Polynesia22 (100) atypicalVilares *et al*. \[[@ref37]\]Portugal486 (12.5)32 (66.7)10 (20.8) mix/recombinantTotal21424 (11.2)133 (62.1)17 (7.9)24 (11.2) mix/recombinant, 14 (6.5) atypical, 2 (0.9) Africa IAIDSHowe and Sibley \[[@ref13]\]USA276 (20)18 (70)3 (10)Genot *et al*. \[[@ref19]\]France11 (100) mix/recombinantTotal286 (21.4)18 (64.3)3 (10.7)1 (3.6) mix/recombinantOcularGrigg *et al*. \[[@ref9]\]France123 (25)3 (25)1 (8.4)5 (41.7) mix/recombinantKhan *et al*. \[[@ref16]\]Brazil113 (27.2)2 (18.2)3 (27.2)3 (27.2) mix/recombinantFekkar *et al*. \[[@ref26]\]France1310 (77)1 (7.7) mix/recombinant, 2 (15.4) Africa ITotal366 (16.7)15 (41.7)4 (11.1)9 (22.2) mix/recombinant, 2 (5.6) Africa IImmunocompetentDemar *et al*. \[[@ref20]\]French Guiana88 (100) atypicalTotal28636 (12.6)166 (58)24 (8.4%)34 (11.9) mix/recombinant, 22 (7.7) atypical, 4 (1.4) Africa I Table 3.Global prevalence rate of clonal genotypes of *T. gondii* based on microsatellite and multilocus PCR-RFLP by continentContinentNo. of isolatesType I\
No. (%)Type II\
No. (%)Type III\
No. (%)Mix/recombinant\
No. (%)Atypical\
No. (%)Africa I\
No. (%)America9719 (19.6)46 (47.4)12 (12.4)3 (3.1)17 (17.5)--Africa161 (6.3)----14 (87.5)1 (6.3)--Europe17316 (9.2)120 (69.4)12 (6.9)17 (9.8)4 (2.3)4 (2.3)Total28636 (12.6)166 (58)24 (8.4)34 (11.9)22 (7.7)4 (1.4)

In ToxoDB genotyping using PCR-RFLP based on multilocus typing, most individuals were infected with genotypes \#9 and \#65 (21.2%). It should be noted that genotype \#65 was isolated from America, and genotype \#9 from Asia ([Table 4](#tab04){ref-type="table"} and [Fig. 3](#fig03){ref-type="fig"}). Table 4.Genetic characterisation of *T. gondii* based on multilocus PCR-RFLP (ToxoDB) in different groupsGroupAuthorCountryType of sampleNo. of isolatesNo. (%) ToxoDB genotypeAIDSFerreira *et al*. \[[@ref23]\]BrazilCSF97 (\#65), 1(\#71), 1 (\#6)Wang *et al*. \[[@ref28]\]ChinaBlood21 (\#9), 1 (\#10)Total117 (63.6) \#65, 1 (9.1) \#71, 1 (9.1) \#6, 1 (9.1) \#9, 1 (9.1) \#10CongenitalFerreira *et al*. \[[@ref23]\]BrazilAmniotic fluid11 (100) \#65Ferreira *et al*. \[[@ref23]\]BrazilBlood11 (100) \#65Carneiro *et al*. \[[@ref27]\]BrazilBlood257 (28) \#11, 1 (4) \#8, 3 (12) \#206, 2 (8) \#41, 2 (8) \#108, 1 (4) \#67, 1 (4) \#207, 1 (4) \#162, 1 (4) \#208, 1 (4) \#36, 1 (4) \#209, 1 (4) \#210, 1 (4) \#211, 1 (4) \#212, 1 mix/recombinantSilva *et al*. \[[@ref33]\]BrazilBlood42 (50) \#108, 1 (25) \# 206, 1 (25) \#229Higa *et al*. \[[@ref32]\]BrazilBlood33 (100) \#166Total347 (20.5) \#11, 4 (11.7) \#108, 4 (11.7) \#206, 3 (8.8) \#166, 2 (5.8) \#65, 2 (5.8) \#41, 1 (2.9) \# 229, 1 (2.9) \#8, 1 (2.9) \#67, 1 (2.9) \#207, 1 (2.9) \#162, 1 (2.9) \#208, 1 (2.9) \#36, 1 (2.9) \#209, 1 (2.9) \#210 1 (2.9) \#211, 1 (2.9) \#212, 1 (2.9) mix/recombinantOcularFerreira *et al*. \[[@ref23]\]BrazilBlood77 (100) \#65CancerWang *et al*. \[[@ref28]\]ChinaBlood21 (50) \#204, 1 (50) \#1Cong *et al*. \[[@ref36]\]ChinaBlood178 (47.1) \#9, 8 (47.1) \#10, 1 (5.8) type I variantWang *et al*. \[[@ref35]\]ChinaBlood99 (100) \#9Total2817 (60.7) \#9, 8 (28.5) \#10, 1 (3.7) \#204, 1 (3.7) \#1, 1 (3.7) type I variantUnknownZhou *et al*. \[[@ref21]\]ChinaND31 (33.3) \#1, 1 (33.3) \#3, 1 (33.3) \#4Acute toxoplasmosisFerreira *et al*. \[[@ref23]\]BrazilBlood/CSF22 (100) \#65Total8518 (21.1) \# 9, 18 (21.1) \#65, 9 (10.5) \#10, 7 (8.2) \#11, 4 (4.7) \#206, 4 (4.7) \#108, 3 (3.5) \#166, 2 (2.3) \#41, 3 (2.3) \#1, 2 (2.3) \#204, 1 (1.1) \#8, 1 (1.1) \#71, 1 (1.1) \#6, 1 (1.1) \#67, 1 (1.1) \#20, 1 (1.1) \#162, 1 (1.1) \#208, 1 (1.1) \#36, 1 (1.1) \#209, 1 (1.1) \#210, 1 (1.1) \#211, 1 (1.1) \#212, 1 (1.1) \#229, 1 (1.1) \#3, 1 (1.1) \#4, 1 (1.1) type I variant[^2]

In addition, the genotyping data of *T. gondii* were divided into several groups, including AIDS, congenital, ocular, acute toxoplasmosis, cancer and immunocompetent. Genetic characterisation of *T. gondii* isolates by PCR-RFLP based on multilocus and microsatellite markers (more than five gene markers) revealed that type II was the most predominant genotype among all groups of human toxoplasmosis (64.3%, 62.1% and 41.7% in AIDS patients, congenital form and ocular toxoplasmosis, respectively). On the other hand, the atypical type (100%) was the most common genotype in the immunocompetent group ([Table 2](#tab02){ref-type="table"}).

Furthermore, our analysis showed that ToxoDB genotype \#65 was the most prevalent in ocular (100%) and AIDS (63.6%) groups. In addition, genotypes \#11 and \#9 were more prevalent in the congenital (20.5%) and other groups (54.5%) ([Table 3](#tab03){ref-type="table"}). Genetic diversity of *T. gondii* isolates in different groups of human and patients is demonstrated in [Table 5](#tab05){ref-type="table"}. Table 5.Genetic diversity of *T. gondii* isolates in different groups of patientsCategoryGroups of patientsToxoDB genotypesAll genotypesOcular\#65AIDS\#6, \#9, \#10, \#65, \#71Congenital\#8, \#11, \#36, \#41, \#65, \#67, \#108, \#162, \#166, \# 206, \#207, \#208, \#209, \#210, \#211, \#212, \#229Cancer\#9, \#10, \#204, \#1, type I variantCommon genotype ToxoDBAll groups\#65Ocular and AIDS\#65Ocular and congenital\#65AIDS and congenital\#65AIDS and cancer\#9Specific genotypesOcular--AIDS\#6, \#71Congenital\#8, \#11, \#36, \#41, \#67, \#108, \#162, \#166, \#206, \#207, \#208, \#209, \#210, \#211, \#212, \#229Cancer--

Discussion {#sec4}
==========

This systematic review is beneficial for understanding the epidemiology of *T. gondii* genotypes in high-risk groups of human. The present study determined the global prevalence rate of *T. gondii* genotypes in AIDS, congenital, ocular toxoplasmosis and other groups of patients, as well as healthy individuals. We used the documented data from the literature collected from different countries.

After searching all the databases, 26 articles were included in this study. According to the results, type II was the most predominant genotype in human toxoplasmosis during 1995--August 2017. Type I lineages are uniformly lethal with absolute lethal dose (LD~100~) of 1 in mice. On the other hand, the type II and III lineages are significantly less virulent with LD~100~⩾103. Moreover, type I or type I-like atypical isolates are more likely to cause intensive retinochoroiditis in patients and the atypical isolates often result in severe acute or disseminated toxoplasmosis in immunocompromised patients \[[@ref5], [@ref13]\].

Various analyses indicate that the prevalence of *T. gondii* genotypes varies in different continents. In current study, the highest and lowest prevalence of *T. gondii* type I strain were reported from American (19.6%) and African continents (6.3%). As mentioned, type I strains of *T. gondii* with LD~100~ of almost one can cause lethal infections in all species of laboratory mice even at low dose inoculations. Therefore, practicing the basic measures seems to be necessary for controlling the disease, especially in the American continent.

According to the literature, type II strains of *T. gondii* are the predominant among human samples in America, and Europe (USA, France, Portugal, etc.). Type II strains of *T. gondii* are of low virulence and high cyst-forming \[[@ref5], [@ref14], [@ref38], [@ref39]\]. We found in our analysis that Europe has the highest prevalence of *T. gondii* genotype type II (69.4%).

Similar to type II, type III strains of *T. gondii* are low virulence with LD~100~⩾10^3^ \[[@ref5]\]. In this review, the highest prevalence of type III strains of *T. gondii* was observed in America (12/97, 12.4%). On the other hand, the lowest prevalence was reported from the European continent (12/173, 6.9%).

According to our study, in the AIDS/HIV group, genotyping of *T. gondii* was performed on 28 isolates using multilocus markers. Our analysis showed that type II strains (18/28, 64.3%) were the most common, followed by type I (6/28, 21.4%), type III (3/28, 10.7%) and mix/recombinant type (1/28, 3.6%). Toxoplasmosis in immunocompromised patients is often due to reactivation of tissue cysts usually leading to severe and life-threatening diseases, toxoplasmic encephalitis and death \[[@ref40]\]. The predominance of type II in the patients may simply reflect the prevalence of type II infection in general population.

In order to determine the genotypes in congenital toxoplasmosis group, 214 *T. gondii* isolates were examined. Totally, 133 (62.1%), 24 (11.2%), 24 (11.2%), 17 (7.9%), 14 (6.5%) and 2 (0.9%) isolates were classified as types II, I, mix/recombinant, III, atypical and Africa I, respectively.

Congenital toxoplasmosis may result in intracerebral calcification, hydrocephalus, mental retardation and retinochoroiditis, which may be present at birth or develop later in life \[[@ref41]\]. The role of genotypes in congenital toxoplasmosis is still controversial. However, it was shown in the study performed by Hutson *et al*. that congenital infections with type II strain are frequently associated with hydrocephalus characteristic patterns \[[@ref42]\].

Rico-Torres *et al*. (2016) in a systematic review study demonstrated that neonatal cases infected with type II strain of *T. gondii* during the first half of pregnancy present severe clinical symptoms. The latter result suggests a crucial role for immature state and response of the foetus in susceptibility to disease \[[@ref43]\]. Among the 26 papers included in this systematic review, only one study had determined the genotype of *T. gondii* in immunocompetent individuals and all the eight samples were infected with the atypical type.

In the ocular toxoplasmosis group, 36 isolates were genotyped and the obtained results showed that type II strains were predominant (15/36, 41.7%), followed by mix/recombinant type (9/36, 25%), type I (6/36, 16.7%), type III (4/36, 11.1%) and Africa I type (2/36, 5.6%) in this group. The previous studies in different countries revealed that ocular toxoplasmosis is associated with type I strain of *T. gondii*.

According to the studies conducted using less than five gene markers, type I strain has the ability for extracellular migration and decreases conversion to the bradyzoite form, in comparison with types II and III \[[@ref44]\]. Our systematic review by more than five gene markers demonstrates that type II is the most prevalent in these patients. The reason for this difference can be attributed to application of more gene markers causing the genotyping to be more precise.

In recent years, researchers have used different markers (about 10--12 markers) of multilocus PCR-RFLP and microsatellites for epidemiology and genotyping studies \[[@ref44]\]. Findings of these studies have indicated a higher genetic diversity among the different groups of patients and healthy individuals. In ToxoDB, 1457 human and animal samples were registered that revealed different ToxoDB genotypes (\#1--\#231). At present, major genotypes such as Chinese 1 (\#9), type Br I (\#6), type Br II (\#11), type Br III (\#8), type IV (\#17) and type 12 (\#4, \#5) were added to the previous list (type I, II, III lineages and atypical or exotic genotypes) \[[@ref38], [@ref45]\].

According to new nomenclature, identified genotypes are Type I (\#10), Type II (\#1 clonal, \#3 variant) and Type III (\#2), kinds of atypical or exotic genotypes, Chinese 1 (\#9, \#10), Type Br I (\#6), Type Br II (\#11), Type Br III (\#8), Type IV (\#17) and Type 12 (\#4, \#5).

Out of the 26 studies included in the current review, 11 studies used multilocus gene markers for genotyping (ToxoDB) and determination of genetic diversity. Our analysis demonstrated that genotype \#65 is predominant among all the different groups of human. Moreover, genotype \#65 is the most prevalent genotype in AIDS and ocular toxoplasmosis groups. However, in the congenital toxoplasmosis group, genotype \#11 was the most common. Genotypes \#6 and \#71 were observed only in the AIDS group. On the other hand, 16 different ToxoDB genotypes, including \#8, \#11, \#36, \#41, \#67, \#108, \#162, \#166, \#206, \#207, \#207, \#209, \#210, \#211, \#212 and \#229 were found in the congenital toxoplasmosis group. It seems that the cause of high-genetic diversity in congenital toxoplasmosis may be due to more sampling from the different regions of the world.

This review indicated that genetic diversity of *T. gondii* was low in Asian and African countries, contrary to the ones in North and South America.

Conclusion {#sec5}
==========

The current study showed that new techniques with more genetic markers for *T. gondii* genotyping, might lead to different results regarding genetic diversity. This is true especially in countries that do not have any data concerning genotyping of this parasite, such as Australia, Western and Southern Africa and Western Asia. Identification of the specific genotype in each area of the world could be valuable in developing new strategies for treatment, vaccination, diagnosis, control and prevention of *T. gondii* in human.
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[^1]: MS, microsatellite Marker; ND, not determined; Mn, multi locus nested-PCR-RFLP (10 markers).

[^2]: ND, not determined.
